Invivyd stock soars on FDA EUA for COVID-19 prophylaxis drug [Seeking Alpha]
Invivyd, Inc. (IVVD)
Company Research
Source: Seeking Alpha
EUA, for its COVID-19 prophylactic drug Pemgarda and released Phase 3 data about a similar product in development. Invivyd stock was up 10% in post-market trading Friday evening. Before market close on Friday, Invivyd said it had received FDA emergency use authorization for its therapy Pemgarda for the pre-exposure prevention of COVID-19 in patients who are moderately-to-severely immunocompromised. Invivyd said Pemgarda, also known as pemivibart, is approved for patients aged 12 year and older who are immunocompromised due to medical conditions, treatments or medications and are unlikely to mount an adequate immune response to a COVID-19 vaccination. The biotech company said that it expects the product to be available in the US “imminently.” It added that it finished 2023 with an estimated $200.6M in cash and equivalents. Invivyd also released interim exploratory data from a Phase 3 study for its drug candidate VYD222, which it is also developing as a pre-exposure prophylaxi
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™GlobeNewswire
- Invivyd Announces CEO TransitionGlobeNewswire
- We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Invivyd, Inc. (NASDAQ: IVVD) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $9.00 price target on the stock.MarketBeat
- Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million [Yahoo! Finance]Yahoo! Finance
IVVD
Earnings
- 11/9/23 - Beat
IVVD
Sec Filings
- 4/22/24 - Form EFFECT
- 4/18/24 - Form ARS
- 4/18/24 - Form DEF
- IVVD's page on the SEC website